Top

Published in:

Open Access 01-12-2013 | Research article

Ramelteon combined with an α₁-blocker decreases nocturia in men with benign prostatic hyperplasia

Authors: Takashi Kawahara, Satoshi Morita, Hiroki Ito, Hideyuki Terao, Ryoko Sakata, Hitoshi Ishiguro, Katsuyuki Tanaka, Hiroshi Miyamoto, Junichi Matsuzaki, Yoshinobu Kubota, Hiroji Uemura

Published in: BMC Urology | Issue 1/2013

Abstract

Background

Nocturia is defined as waking one or more times during the night due to the urge to void. Recently, the effectiveness of several sedatives and analgesics for nocturia has been reported. We herein investigated the effects of ramelteon, an antioxidant and sleep inducer, on nocturia unresponsive to α1-blocker monotherapy in males with lower urinary tract symptoms (LUTS) as a pilot study.

Methods

Subjects were 19 patients who had LUTS suggestive of benign prostate hyperplasia, received α₁-blockers (tamsulosin, silodosin, or naftopidil), and continued to have two or more episodes of nocturia per night before starting ramelteon. Ramelteon at 8 mg once daily for one month was added to the α₁-blocker. A self-administered questionnaire including the International Prostate Symptom Score (IPSS), quality of life (QoL) index, Overactive Bladder Symptom Score (OABSS), and Nocturia Quality-of-Life Questionnaire (N-QOL) were assessed before and one month after starting ramelteon.

Results

The mean score on IPSS question 7 (nocturia) decreased significantly from 2.88 before starting ramelteon to 2.41 one month after starting the medication (P = 0.03). The mean total OABSS decreased significantly from 6.31 to 5.38 (P = 0.03), and the mean for OABSS question 2 (nighttime frequency of nocturia) also significantly decreased from 2.63 to 2.13 (P = 0.01). The mean total N-QOL score did not change significantly. Two patients had dizziness; the remaining patients had no adverse drug-related events.

Conclusions

Ramelteon in combination with an α₁-blocker could be a treatment option for reducing nocturia in men with BPH.

Available only for authorised users

van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, Jennum P, Johnson T, Lose G, Mattiasson A, et al: The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002, 21 (2): 179-183. 10.1002/nau.10053.CrossRefPubMed

Johnson TM, Markland AD, Goode PS, Vaughan CP, Colli JL, Ouslander JG, Redden DT, McGwin G, Burgio KL: Efficacy of adding behavioural treatment or antimuscarinic drug therapy to alpha-blocker therapy in men with nocturia. BJU Int. 2013, 2013: 2013-

Weiss JPBJ: Nocturnal polyuria versus overactive bladder in nocturia. Urology. 2002, 60 (5 Suppl 1): 28-32.CrossRefPubMed

Appell RASP: Nocturia: etiology, diagnosis, and treatment. Neurourol Urodyn. 2008, 27 (1): 34-39. 10.1002/nau.20484.CrossRefPubMed

Middelkoop HA, den Doel DA S-v, Neven AK, Kamphuisen HA, Springer CP: Subjective sleep characteristics of 1,485 males and females aged 50–93: effects of sex and age, and factors related to self-evaluated quality of sleep. J Gerontol A Biol Sci Med Sci. 1996, 51 (3): M108-M115.CrossRefPubMed

Tsujimura A, Takao T, Miyagawa Y, Yamamoto K, Fukuhara S, Nakayama J, Kiuchi H, Suganuma N, Nakamura T, Kumano-Go T, et al: Urgency is an independent factor for sleep disturbance in men with obstructive sleep apnea. Urology. 2010, 76 (4): 967-970. 10.1016/j.urology.2010.01.070.CrossRefPubMed

Kim SO, Choi HS, Kim YJ, Kim HS, Hwang IS, Hwang EC, Oh KJ, Jung SI, Kang TW, Kwon D, et al: Impact of nocturia on health-related quality of life and medical outcomes study sleep score in men. Int Neurourol J. 2011, 15 (2): 82-86. 10.5213/inj.2011.15.2.82.CrossRefPubMedPubMedCentral

Kaye M: Nocturia: a blinded, randomized, parallel placebo-controlled self-study of the effect of 5 different sedatives and analgesics. Can Urol Assoc J. 2008, 2 (6): 604-608.PubMedPubMedCentral

Drake MJ, Mills IW, Noble JG: Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol. 2004, 171 (3): 1199-1202. 10.1097/01.ju.0000110442.47593.ea.CrossRefPubMed

10.

Shimizu NSK, Nozawa M: Efficacy of ramelteon in patients with insomnia and nocturia. LUTS. 2012, 10.1111/j.1757-5672.2012.00166.x. Epub ahead of print

11.

Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005, 48 (2): 301-310. 10.1016/j.neuropharm.2004.09.007.CrossRefPubMed

12.

Uchiyama M, Hamamura M, Kuwano T, Nishiyama H, Nagata H, Uchimura N: Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med. 2011, 12 (2): 119-126. 10.1016/j.sleep.2010.08.010.CrossRefPubMed

13.

Uchiyama M, Hamamura M, Kuwano T, Nagata H, Hashimoto T, Ogawa A, Uchimura N: Long-term safety and efficacy of ramelteon in Japanese patients with chronic insomnia. Sleep Med. 2011, 12 (2): 127-133. 10.1016/j.sleep.2010.10.006.CrossRefPubMed

14.

Barry MJ, Williford WO, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT:The American Urological Association symptom indexfor benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol. 1992, 148 (5): 1549-1557.PubMed

15.

Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009, 56 (3): 534-541. 10.1016/j.eururo.2008.11.026.CrossRefPubMed

16.

Moore KN, Valiquette L, Chetner MP, Byrniak S, Herbison GP: Return to continence after radical retropubic prostatectomy: a randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. Urology. 2008, 72 (6): 1280-1286. 10.1016/j.urology.2007.12.034.CrossRefPubMed

17.

Keyes M, Miller S, Moravan V, Pickles T, McKenzie M, Pai H, Liu M, Kwan W, Agranovich A, Spadinger I, et al: Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys. 2009, 73 (4): 1023-1032. 10.1016/j.ijrobp.2008.05.022.CrossRefPubMed

18.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003, 61 (1): 37-49. 10.1016/S0090-4295(02)02243-4.CrossRefPubMed

19.

Michel MC, Chapple CR: Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). Eur Urol. 2006, 49 (3): 501-508. 10.1016/j.eururo.2005.12.024. discussion 508–509CrossRefPubMed

20.

Yoshimura K, Ohara H, Ichioka K, Terada N, Matsui Y, Terai A, Arai Y: Nocturia and benign prostatic hyperplasia. Urology. 2003, 61 (4): 786-790. 10.1016/S0090-4295(02)02444-5.CrossRefPubMed

21.

Schwinn DA, Roehrborn CG: Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008, 15 (3): 193-199. 10.1111/j.1442-2042.2007.01956.x.CrossRefPubMedPubMedCentral

22.

Brawer MK, Lin DW, Williford WO, Jones K, Lepor H: Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate. 1999, 39 (4): 234-239. 10.1002/(SICI)1097-0045(19990601)39:4<234::AID-PROS3>3.0.CO;2-4.CrossRefPubMed

23.

Homma Y, Araki I, Igawa Y, Ozono S, Gotoh M, Yamanishi T, Yokoyama O, Yoshida M: Clinical guideline for male lower urinary tract symptoms. Int J Urol. 2009, 16 (10): 775-790. 10.1111/j.1442-2042.2009.02369.x.CrossRefPubMed

24.

McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE, Gonzalez CM, Kaplan SA, Penson DF, et al: Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011, 185 (5): 1793-1803. 10.1016/j.juro.2011.01.074.CrossRefPubMed

25.

Committee for Establishment of the Clinical Guidelines for Nocturia of the Neurogenic Bladder Society:: Clinical guidelines for nocturia. Int J Urol. 2010, 17 (5): 397-409.CrossRef

26.

Bruskewitz RC, Larsen EH, Madsen PO, Dorflinger T: 3-year followup of urinary symptoms after transurethral resection of the prostate. J Urol. 1986, 136 (3): 613-615.PubMed

27.

Okada S, Watanabe H, Kojima Y, Yanai Y, Sasaki S, Kohri K: Loxoprofen sodium treatment for elderly men with refractory nocturia: effect on night-time urine production. Int J Urol. 2008, 15 (5): 462-464. 10.1111/j.1442-2042.2008.02021.x.CrossRefPubMed

28.

Abraham L, Hareendran A, Mills IW, Martin ML, Abrams P, Drake MJ, MacDonagh RP, Noble JG: Development and validation of a quality-of-life measure for men with nocturia. Urology. 2004, 63 (3): 481-486. 10.1016/j.urology.2003.10.019.CrossRefPubMed

29.

Klerman H, St Hilaire MA, Kronauer RE, Gooley JJ, Gronfier C, Hull JT, Lockley SW, Santhi N, Wang W, Klerman EB: Analysis method and experimental conditions affect computed circadian phase from melatonin data. PLoS One. 2012, 7 (4): e33836-10.1371/journal.pone.0033836.CrossRefPubMedPubMedCentral

30.

Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O: Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology. 2006, 68 (2): 318-323. 10.1016/j.urology.2006.02.042.CrossRefPubMed

31.

Gotoh M, Homma Y, Yokoyama O, Nishizawa O: Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology. 2011, 78 (4): 768-773. 10.1016/j.urology.2011.06.020.CrossRefPubMed

32.

Kim K, Uchiyama M, Okawa M, Liu X, Ogihara R: An epidemiological study of insomnia among the Japanese general population. Sleep. 2000, 23 (1): 41-47.PubMed

33.

Liu X, Uchiyama M, Kim K, Okawa M, Shibui K, Kudo Y, Doi Y, Minowa M, Ogihara R: Sleep loss and daytime sleepiness in the general adult population of Japan. Psychiatry Res. 2000, 93 (1): 1-11. 10.1016/S0165-1781(99)00119-5.CrossRefPubMed

34.

Ramakrishnan K, Scheid DC: Treatment options for insomnia. Am Fam Physician. 2007, 76 (4): 517-526.PubMed

35.

Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M: The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007, 22 (9): 1335-1350. 10.1007/s11606-007-0251-z.CrossRefPubMedPubMedCentral

36.

Doghramji K: Melatonin and its receptors: a new class of sleep-promoting agents. J Clin Sleep Med. 2007, 3 (5 Suppl): S17-S23.PubMedPubMedCentral

37.

Nowak JZ, Zawilska JB: Melatonin and its physiological and therapeutic properties. Pharm World Sci. 1998, 20 (1): 18-27. 10.1023/A:1008688724058.CrossRefPubMed

38.

Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T: Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int J Urol. 2006, 13 (1): 15-20. 10.1111/j.1442-2042.2006.01222.x.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/13/30/prepub

Title: Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia
Authors: Takashi Kawahara
Satoshi Morita
Hiroki Ito
Hideyuki Terao
Ryoko Sakata
Hitoshi Ishiguro
Katsuyuki Tanaka
Hiroshi Miyamoto
Junichi Matsuzaki
Yoshinobu Kubota
Hiroji Uemura
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: BMC Urology / Issue 1/2013
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/1471-2490-13-30

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ramelteon combined with an α₁-blocker decreases nocturia in men with benign prostatic hyperplasia

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Relationships between perioperative physical activity and urinary incontinence after radical prostatectomy: an observational study

Renal papillary calcification and the development of calcium oxalate monohydrate papillary renal calculi: a case series study

Laparoendoscopic single site adrenalectomy: initial results of cosmetic satisfaction and the potential for postoperative pain reduction

Altered expression of caveolin 2 and 3 in smooth muscle of rat urinary bladder by 17β-estradiol

Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection

A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy